The key driver of this market is an increase in the prevalence of chronic diseases and thriving demand and development of monoclonal antibodies (mAbs) and immunotherapy drugs. Immunotherapy refers to the treatment of a disease by enhancing, inducing, or suppressing an immune response.

Across the globe, the increasing prevalence of chronic diseases has become a major healthcare burden, as it affects people in high-income as well as low and middle-income countries (LMIC). According to a World Health Organization report, the fact that cancer led to an estimated 9.6 million deaths in 2018 firmly cements this claim. The organization further reported that around 70% of all deaths from cancer occur in LMICs.

Download Report Sample at:https://www.psmarketresearch.com/market-analysis/immunotherapy-drugs-market/report-sample

Furthermore, in a report of the International Agency for Research on Cancer (IARC) in 2018, it is estimated that around 18.1 million people were suffering from cancer globally, and the number is projected to reach 29.5 million by 2040. Similarly, a study conducted between 2005 and 2015 by the American Medical Association found that cancer cases increased by 33% during this period, of which 16.4% cases were due to aging population. Hence, the growing use of immunotherapy drugs to meet the increasing prevalence of chronic diseases in the elderly is driving the immunotherapy drugs market.

That same month, Allogene Therapeutics Inc. and Pfizer Inc. signed an asset contribution agreement to use Pfizer’s allogeneic CAR-T therapy, which is investigational immune cell therapy, for cancer. This agreement provided an opportunity for Pfizer Inc. to continue the development of the CAR-T therapy. Other players operating in the global immunotherapy drugs market, such as AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sanofi, Medigene AG, AbbVie Inc, Johnson & Johnson, Amgen Inc., Merck & Co. Inc., GlaxoSmithKline plc, C. H. Boehringer Sohn AG & Co. KG, Novartis International AG, Takeda Pharmaceutical Company Limited, and Celgene Corporation, are taking similar steps.

Hence, as more people get affected by chronic diseases in the future, the immunotherapy drugs sector will continue to prosper.

According to the new market research report "Immunotherapy Drugs Market by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific) - Global Forecast to 2021", published by MarketsandMarkets™,The global immunotherapy drugs market is projected to reach USD 201.52 Billion by 2021 from USD 108.41 Billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021.

Don’t miss out on business opportunities in Immunotherapy Drugs Market

Increasing adoption of targeted therapies with fewer side effects, quicker drug approval processes, and high prevalence rate of lifestyle diseases are major growth drivers of this market. On the other hand, the high cost of immunotherapy treatment, and high attrition rate in the product development cycle are the major factors hindering the growth of the market.  However, rising opportunities in the emerging markets, and immunotherapy as an alternative to chemotherapy for first line treatment are the factors supporting the growth of the market.

Target Audience

Pharmaceuticals Manufacturers

Research & Academic Institutions

Hospitals and clinics

Contract Manufacturers

Contract Research Organizations

To know about the assumptions considered for the study, download the pdf brochure

Browse and in-depth TOC on "Immunotherapy drugs Market"

79  - Tables

44  - Figures

174  - Pages

Immunotherapy drugs Market, by Therapy Area

• Cancer
• Solid Tumor
• Malignant
• Autoimmune & Inflammatory Diseases
• Infectious Diseases
• Others

Get Free 10% customization:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=137717755

Company Information

Detailed analysis and profiling of additional market players

The global immunotherapy drugs market is projected to reach USD 201.52 Billion by 2021 from USD 108.41 Billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021.

Increasing adoption of targeted therapies with fewer side effects, quicker drug approval processes, and high prevalence rate of lifestyle diseases are major growth drivers of this market. On the other hand, the high cost of immunotherapy treatment, and high attrition rate in the product development cycle are the major factors hindering the growth of the market.  However, rising opportunities in the emerging markets, and immunotherapy as an alternative to chemotherapy for first line treatment are the factors supporting the growth of the market.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Immunotherapy is the management of a disease by enhancing, suppressing, or inducing an immune response. Some immunotherapies are designed to magnify or elicit an immune response. They are known as activation immunotherapies. However, some immunotherapies that suppress or reduce the immune response are known as suppression immunotherapies. Cell-based immunotherapies are useful for some types of cancers. Immune effector cells includingmacrophages, dendritic cells, lymphocytes, cytotoxic T lymphocytes (CTL), natural killer cells (NK Cell), etc., work collectively to protect the body against cancer by aiming at abnormal antigens articulated on the facade of the tumor cells.Therapies including granulocyte colony-stimulating factor (G-CSF), imiquimod, interferons as well as parts of cellular membrane from bacteria are approved for medical use. Some of the others such as IL-7, IL-2, IL-12, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans anda variety of chemokines are involved in preclinical and clinical studies.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/525

An increase in the prevalence of cancer and a number of autoimmune diseases, the demand for immunotherapy drugs is likely to increase. Moreover, with the rising need for mAbs, the immunotherapy drugs market is anticipated to have a positive outlook till the end of the forecast period 2016-2024. MAbs have a high affinity towards the specific disease cells as well as areas that require treatment. Accordingly, they can be utilized for therapies such asantibody-directed enzyme prodrug therapy and radio immunotherapy. The increaseduse of these antibodies in the drug development processis likely toaid to boost the market’s revenue making capacity over the forecast period.

Another important factor driving the growth prospects ofthe global immunotherapy drugs market is the materialization of biosimilars. Dissimilarto generic drugs that have active pharmaceutical ingredients alikeoriginal drugs, biosimilars are nearly identical to their creator biologic compounds. In view of the fact that biosimilars are less expensive and aid to make managementof diseases more reachable for the patients than biologics, the sale of biosimilars among the patients and hospitals alike is likely to riseconsiderably during the forecast period thereby augmenting the overall growth of the immunotherapy drugs market.

Immunotherapy Drugs Market Taxonomy

On the basis of product type,

• Vaccines

• mAbs

• Non-specific immunotherapies

• Immune checkpoint inhibitors

On the basis of therapy area,

• Cancer

• Autoimmune and Inflammatory Diseases

• Infectious Diseases

• Other Therapy Areas

Get Sample Copy Of This Exclusive Report: https://www.coherentmarketinsights.com/insight/request-sample/525

According to National Cancer Institute, around 1,685,210 new cases of cancer are likely to be diagnosed in the U.S. in 2016 and about 595,690 people are estimated to die from the disease. Since immunotherapy is used as a first line of treatment in the management of cancer, the market immunotherapy drugs market will grow accordingly. North America is the largest region in the global immunotherapy drugs market and is expected to retain its dominance over the forecast period. Asia Pacific is likely to be the fastest-growing marketover the forecast period. The elevated growth of this region can mainly be attributed to low cost of manufacturing of these drugs in the region, rising occurrence of cancer and favorable regulatory framework in this region.

Some of the companies operating in the immunotherapy drugs market in the current scenario are GlaxoSmithKline, F. Hoffmann-La Roche AG, AbbVie, In., Merck & Co., Inc. Amgen, Inc., Bristol-Myers Squibb, Eli Lilly and Company, Novartis International AG, AstraZeneca plc and Johnson & Johnson. Click To Read More On Immunotherapy Drugs Market